Tag Archives: HCV

Cytomegalovirus IgM Antibody Detection and Hepatitis B and C Coinfections among HIV Patients in Ado-Ekiti, Nigeria (Published)

Opportunistic viral infections such as Cytomegalovirus (CMV), Hepatitis B (HBV) and C (HCV) are often prevalent in HIV patients undergoing antiretroviral therapy (ART) thereby shortening the life span of infected patients. The co-infection of CMV, HBV and HCV among HIV positive patients attending ART clinics across hospitals in Ekiti State, Nigeria, were studied. Ninety-two (92) blood samples from HIV positive individuals (males, pregnant females and non-pregnant females) were collected and serologically screened for CMV antibodies (IgM) using enzyme linked immunosorbent assay (ELISA) while HBV and HCV surface antigen were determined using standard test kit. The viral loads were determined using COBAS® AmpliPrep / COBAS® TaqMan® systems. The occurrence of single or coinfection of HIV-patients with respect to their sampling class were also determined and expressed in percentage. Of samples screened, the total positive occurrence rates of 23.16±1.78%, 11.20±1.46% and 30.21±2.67% were observed for CMV, HBV and HCV while 35.43±1.85% of total respondents tested negative to all the viruses screened in this study. The total viral loads were 10184 copies/ml for CMV, 5679 copies/ml for HBV and 12678 copies/ml for HCV. For the coinfections, respondents with HBV+HCV had a total occurrence of 31.80±2.25% (13294 copies/ml) while HCV+CMV had total occurrence of 44.40±3.18% (51783 copies/ml), CMV+HBV had total occurrence of 19.25±1.67% (8679 copies/ml) and CMV+HCV+HBV had a total occurrence of 9.50±1.35% (586 copies/ml). This high prevalence rate of CMV with Hepatitis co-infection among these HIV positive individuals further support the role of viral reactivation in immunocompromised patients.

Keywords: CMV, Co-infection, ELISA, HBV, HCV, HIV, qPCR

Incidences of Hepatitis B Surface Antigen and Hepatitis C Antibodies in Diabetics Patient at Oouth (Published)

In recent time, controversy have been stirred up over the aetiology of liver failure in diabetic patients. Hence, this study was carried out to determine the incidence of Hapatitis B surface antigen and Hapatitis C antibodies in diabetic patients at             OOUTH. 5ml venous blood samples was collected from the diabetic patients, centrifuged at 1500 rpm for 5minutes and screened for HBV and HCV using ELISA and Diaspot Kits respectively. Out of the 230 diabetic patients screened for Hepatitis Virus Infection, 49 (19.6%) of them were positive while 185 (80.4%) were negative. HBV infection was highest in frequency by 43 (95.6%), followed by HBV and HCV co-infection, with a frequency of 2 (4.4%). Gender and ages of diabetic patients were observed not to have significant relationship with the incidence of viral hepatitis infection (P>0.05). Incidence of viral hepatitis was significantly higher in uneducated and widowed diabetic patients (P<0.05). Higher incidence of viral hepatitis infection was found to be significantly associated with tattooing (P<0.05) while no significant association was observed between same infection and each of alcoholism, blood transfusion, previous surgery and number of sex partners (P>0.05). When the diagnostic test result of diaspot was compared with ELISA, sensitivity of 11.1% and 82.2% were respectively observed (P<0.05).In conclusion, this study has established that the incidence of viral hepatitis was higher among diabetic patients with no formal education, those who are widows, and tattoo. It was further discovered that diaspot is less sensitive compared to ELISA

Keywords: Aetiology, Diabetes, ELISA, HBV, HCV, Hepatitis, Liver

Molecular Characterization of Hepatitis C Virus Strain Circulated In Chronically Infected Patients in Abidjan (Cote-D’ivoire) (Published)

Viral hepatitis C (HCV) is a public health problem. The therapeutic management and in particular the duration of treatment depends on the viral genotype. HCV is poorly documented in the population and there are few data on the different genotypes and subtypes of HCV circulating in Côte d’Ivoire. In this context, the main objective of this study was to study the genetic variability of the HCV virus in infected patients in Abidjan. We conducted a cross-sectional study at CIRBA from June 2015 to June 2017 which included adult patients with a Viral Load > 1000 IU/mL. HCV genotyping was performed by amplification of the NS5B region followed by sequencing with an ABI 3130 sequencer (Applied Biosystems, Courtaboeuf, France). Phylogenetic trees were produced using MEGA 7 software and genotypes were confirmed using online software (http://hcv.geno2pheno.org). In this study 94 subjects were included. The genotypes encountered were genotypes 1, 2 and 4 with a prevalence of 46%, 52% and 2% respectively. These strains were divided into 17 subtypes genotype 1 : 6 subtypes 1a, 1b, 1c, 1d, 1i, 1k, genotype 2 : 9 subtypes 2a, 2b, 2c, 2c/k, 2f, 2j, 2k, 2l, 2r and 2 subtypes 4f and 4r for genotype 4. The study allowed the implementation of a genotyping technique and monitoring showed that genotypes 1 and 2 are predominant in Côte d’Ivoire. The circulation of genotype 4 is noted.

Keywords: HCV, Sequencing, Treatment., genotype.

Interferon Inducible Protein-10 Level and Il28b Gene Polymorphism as Predictors of the Response to Pegylated Interferon / Ribavirin Therapy in Egyptian Hcv Patients (Published)

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The highest prevalence of HCV infection was reported to occur in Egypt. It is crucial to determine the predictors of Sustained Viral Response (SVR) to Pegylated Interferon (peg-INF) / Ribavirin (RBV) therapy in chronic HCV Egyptians, in order to select the patients who will get benefit from this costly therapy that has frequent side effects. Pretreatment  serum interferon Inducible Protein-10 (IP-10) level measurement and genotyping for IL28B rs12979860 polymorphism, were carried out on 82 Egyptian chronic HCV patients receiving peg-INF/ RBV dual therapy for 48 weeks. It was revealed that patients with SVR had lower baseline IP-10 level. The baseline IP-10 level with the best sensitivity and specificity for identifying SVR was 499.02 pg/ml, with 100% specificity and 82% sensitivity. Moreover, the response rates to this dual therapy were 86.2%, 52.9%, 0.0% for genotypes CC, CT, and TT of the IL28B rs12979860 polymorphism respectively. So it can be said that carriage of a C allele is favorably associated with treatment response. Also a statistically significant lower serum IP-10 baseline level was found in the homozygous carriers of favorable CC genotype as compared with carriers of CT and TT genotypes. In conclusion, baseline serum IP-10 and genotyping for IL28B rs12979860 polymorphism are of significant value in predicting the response to peg-INF/ RBV dual therapy in Egyptian chronic HCV infection patients

Keywords: HCV, IL28B, IP-10, Interferon, ribavirin., sustained virological response

Interferon Inducible Protein-10 Level and IL28B Gene Polymorphism as predictors of the Response to Pegylated Interferon / Ribavirin therapy In Egyptian HCV Patients (Published)

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The highest prevalence of HCV infection was reported to occur in Egypt. It is crucial to determine the predictors of Sustained Viral Response (SVR) to Pegylated Interferon (peg-INF) / Ribavirin (RBV) therapy in chronic HCV Egyptians, in order to select the patients who will get benefit from this costly therapy that has frequent side effects. Pretreatment  serum interferon Inducible Protein-10 (IP-10) level measurement and genotyping for IL28B rs12979860 polymorphism, were carried out on 82 Egyptian chronic HCV patients receiving peg-INF/ RBV dual therapy for 48 weeks. It was revealed that patients with SVR had lower baseline IP-10 level. The baseline IP-10 level with the best sensitivity and specificity for identifying SVR was 499.02 pg/ml, with 100% specificity and 82% sensitivity. Moreover, the response rates to this dual therapy were 86.2%, 52.9%, 0.0% for genotypes CC, CT, and TT of the IL28B rs12979860 polymorphism respectively. So it can be said that carriage of a C allele is favorably associated with treatment response. Also a statistically significant lower serum IP-10 baseline level was found in the homozygous carriers of favorable CC genotype as compared with carriers of CT and TT genotypes. In conclusion, baseline serum IP-10 and genotyping for IL28B rs12979860 polymorphism are of significant value in predicting the response to peg-INF/ RBV dual therapy in Egyptian chronic HCV infection patients

 

Keywords: HCV, IL28B, IP-10, Interferon, ribavirin., sustained virological response